Perioperative Nivolumab Shows Long-Term EFS, Favorable OS in Resectable NSCLC
Building on positive event-free survival (EFS) and overall survival (OS) rates in the original analysis of CheckMate 77T, new results indicate sustained survival over 3 years following treatment with nivolumab compared with placebo in non-small cell lung cancer (NSCLC).